CancerDrs

Lung Cancer clinical trials in Colorado

52 actively recruiting lung cancer trials at 27 sites across Colorado.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • Rocky Mountain Regional VA Medical Center — Aurora, Colorado
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • Boulder Community Foothills Hospital — Boulder, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04181060
Sites in Colorado:
  • Rocky Mountain Cancer Centers-Aurora — Aurora, Colorado
  • The Medical Center of Aurora — Aurora, Colorado
  • Boulder Community Foothills Hospital — Boulder, Colorado
  • Rocky Mountain Cancer Centers-Boulder — Boulder, Colorado
  • Rocky Mountain Cancer Centers - Centennial — Centennial, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Colorado:
  • Local Institution - 007-872-H — Aurora, Colorado
  • Local Institution - 007-872-D — Boulder, Colorado
  • Local Institution - 007-872-L — Centennial, Colorado
  • Local Institution - 007-872-C — Colorado Springs, Colorado
  • Local Institution - 007-872-K — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…

Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Colorado:
  • Rocky Mountain Cancer Centers,LLP — Denver, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Colorado:
  • UCHealth Memorial Hospital-Heme Onc ( Site 0052) — Colorado Springs, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus ( Site 0151) — Aurora, Colorado
  • UCHealth Memorial Hospital Central ( Site 0125) — Colorado Springs, Colorado
  • Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) — Greeley, Colorado
  • Centura Health - St. Anthony North Health Campus ( Site 0189) — Westminster, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361497
Sites in Colorado:
  • Local Institution - 0585 — Golden, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of meta…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06422143
Sites in Colorado:
  • Intermountain Health Cancer Center Lutheran Hospital ( Site 0119) — Golden, Colorado
  • Intermountain Health St. Mary's Regional Hospital ( Site 0116) — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan an…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06170788
Sites in Colorado:
  • Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0132) — Grand Junction, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Colorado:
  • UCHealth University of Colorado Hospital — Aurora, Colorado
  • UCHealth Memorial Hospital Central — Colorado Springs, Colorado
  • Memorial Hospital North — Colorado Springs, Colorado
  • Poudre Valley Hospital — Fort Collins, Colorado
  • Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% …

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT05609578
Sites in Colorado:
  • Local Institution - 017-872-I — Aurora, Colorado
  • Local Institution - 017-872-G — Boulder, Colorado
  • Local Institution - 017-872-D — Colorado Springs, Colorado
  • Local Institution - 017-872-J — Colorado Springs, Colorado
  • Local Institution - 017-872-B — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Colorado:
  • Rocky Mountain Cancer Center — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disea…

Sponsor: AbbVie
NCT ID: NCT06772623
Sites in Colorado:
  • University Of Colorado - Anschutz Medical Campus /ID# 269069 — Aurora, Colorado
  • Rocky Mountain Cancer Centers - Lone Tree /ID# 272603 — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Colorado:
  • Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Colorado:
  • Avenzo Therapeutics Recruiting Site — Denver, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection…

Sponsor: Genprex, Inc.
NCT ID: NCT05703971
Sites in Colorado:
  • Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy can…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780137
Sites in Colorado:
  • University of Colorado Anschutz Medical Campus ( Site 1110) — Aurora, Colorado
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06788912
Sites in Colorado:
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8011) — Lone Tree, Colorado
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 i…

Sponsor: TRIANA Biomedicines, Inc.
NCT ID: NCT07491497
Sites in Colorado:
  • University of Colorado Cancer Center — Aurora, Colorado
View on ClinicalTrials.gov →

Showing 25 of 52 trials with sites in Colorado. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25